- Home
- OCUL
as of 03-03-2026 3:38pm EST
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BEDFORD |
| Market Cap: | 1.9B | IPO Year: | 2014 |
| Target Price: | $22.90 | AVG Volume (30 days): | 7.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.42 | EPS Growth: | -16.39 |
| 52 Week Low/High: | $6.23 - $16.44 | Next Earning Date: | 05-06-2026 |
| Revenue: | $1,990,000 | Revenue Growth: | 3.48% |
| Revenue Growth (this year): | 9.35% | Revenue Growth (next year): | 92.88% |
| P/E Ratio: | -7.68 | Index: | N/A |
| Free Cash Flow: | -216893000.0 | FCF Growth: | N/A |
AI-Powered OCUL Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Ocular Therapeutix Inc. (OCUL)
Chief Strategy Officer
Avg Cost/Share
$8.28
Shares
1,759
Total Value
$14,564.52
Owned After
330,653
SEC Form 4
See Remarks
Avg Cost/Share
$8.28
Shares
20,056
Total Value
$166,063.68
Owned After
3,013,022
SEC Form 4
Chief Development Officer
Avg Cost/Share
$8.28
Shares
2,810
Total Value
$23,266.80
Owned After
269,108
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$8.28
Shares
3,057
Total Value
$25,311.96
Owned After
323,368
SEC Form 4
Director
Avg Cost/Share
$7.66
Shares
60,229
Total Value
$461,354.14
Owned After
246,933
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$7.74
Shares
3,510
Total Value
$27,167.40
Owned After
314,907
SEC Form 4
Chief Strategy Officer
Avg Cost/Share
$9.04
Shares
10,348
Total Value
$93,545.92
Owned After
330,653
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$9.04
Shares
11,446
Total Value
$103,471.84
Owned After
366,356
SEC Form 4
See Remarks
Avg Cost/Share
$9.04
Shares
124,882
Total Value
$1,128,933.28
Owned After
3,013,022
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$9.04
Shares
7,863
Total Value
$71,081.52
Owned After
314,907
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Nayak Sanjay | OCUL | Chief Strategy Officer | Feb 23, 2026 | Sell | $8.28 | 1,759 | $14,564.52 | 330,653 | |
| Dugel Pravin | OCUL | See Remarks | Feb 23, 2026 | Sell | $8.28 | 20,056 | $166,063.68 | 3,013,022 | |
| Kaiser Peter | OCUL | Chief Development Officer | Feb 23, 2026 | Sell | $8.28 | 2,810 | $23,266.80 | 269,108 | |
| Heier Jeffrey S. | OCUL | Chief Scientific Officer | Feb 23, 2026 | Sell | $8.28 | 3,057 | $25,311.96 | 323,368 | |
| LINDSTROM RICHARD L MD | OCUL | Director | Feb 20, 2026 | Buy | $7.66 | 60,229 | $461,354.14 | 246,933 | |
| Waheed Nadia | OCUL | Chief Medical Officer | Feb 20, 2026 | Sell | $7.74 | 3,510 | $27,167.40 | 314,907 | |
| Nayak Sanjay | OCUL | Chief Strategy Officer | Feb 12, 2026 | Sell | $9.04 | 10,348 | $93,545.92 | 330,653 | |
| Notman Donald | OCUL | Chief Operating Officer | Feb 12, 2026 | Sell | $9.04 | 11,446 | $103,471.84 | 366,356 | |
| Dugel Pravin | OCUL | See Remarks | Feb 12, 2026 | Sell | $9.04 | 124,882 | $1,128,933.28 | 3,013,022 | |
| Waheed Nadia | OCUL | Chief Medical Officer | Feb 12, 2026 | Sell | $9.04 | 7,863 | $71,081.52 | 314,907 |
Compare OCUL vs Leading Stocks
See how OCUL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "OCUL Ocular Therapeutix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.